Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)

NCT04730349 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT04730349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04730349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Terminated
Start date
June 3, 2021
Completion date
June 22, 2022
Enrollment
15 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, ewing sarcoma, high-grade glioma, leukemia and lymphoma, medulloblastoma, miscellaneous brain tumors, miscellaneous solid tumors, neuroblastoma, relapsed, refractory malignant neoplasms, rhabdomyosarcoma